Clinical Trials
137 trialsMAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Spotlight
Astellas Pharma Inc
LEAP-005
Merck Sharp & Dohme LLC
MEDIOLA
AstraZeneca
GLOW
Astellas Pharma Inc
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Safety and Efficacy of Trastuzumab BS
Pfizer
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-859
Merck Sharp & Dohme LLC
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
MK-3475-811
Merck Sharp & Dohme LLC
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ConsortiumIO
Vedanta Biosciences, Inc.
DisTinGuish
Leap Therapeutics, Inc.
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Hanmi Pharmaceutical Company Limited
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
CheckMate649
Bristol-Myers Squibb
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
MAHOGANY
MacroGenics
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
nextHERIZON
Imugene Limited
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
MasterKey-01
Black Diamond Therapeutics, Inc.
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
A Study of TAS-120 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
MacroGenics
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Pfizer
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Highlight Therapeutics
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
DG-06
AstraZeneca
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
BeiGene
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
A Safety and Efficacy Study in Patients With Gastric Cancer
Taiho Oncology, Inc.
DIGEST
Taiho Oncology, Inc.
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Janssen Pharmaceutical K.K.
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Taiho Oncology, Inc.
JAVELIN Medley
Pfizer
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.